A BIOAVAILABILITY/BIOEQUIVALENCE AND PHARMACOKINETIC STUDY OF TWO ORAL DOSES OF TORASEMIDE (5 AND 10 mg): PROLONGED-RELEASE VERSUS THE CONVENTIONAL FORMULATION-Reference-Cited by-同舟云学术

A BIOAVAILABILITY/BIOEQUIVALENCE AND PHARMACOKINETIC STUDY OF TWO ORAL DOSES OF TORASEMIDE (5 AND 10 mg): PROLONGED-RELEASE VERSUS THE CONVENTIONAL FORMULATION

Published:2009-05 Issue:5-6 Volume:36 Page:469-477
ISSN:0305-1870
Container-title:Clinical and Experimental Pharmacology and Physiology
language:en
Short-container-title:

Author:

Barbanoj MJ,Ballester MR,Antonijoan RM,Puntes M,Gropper S,Santos B,Albet C,Guglietta A

Publisher

Wiley

Subject

Physiology (medical),Pharmacology,Physiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1440-1681.2008.05089.x/fullpdf

Reference27 articles.

1. Torasemide. A review of its pharmacological properties and therapeutic potential;Friedel;Drugs,1991

2. Torasemide. An update of its pharmacological properties and therapeutic efficacy;Dunn;Drugs,1995

3. Tubular chloride transport and the mode of action of some diuretics;Burg;Kidney Int,1976

4. How do loop diuretics act?;Wittner;Drugs,1991

5. Clinical pharmacology of loop diuretics;Brater;Drugs,1991

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Critical Review of Clinical Pharmacokinetics of Torasemide;Therapeutic Drug Monitoring;2024-01-01

2. Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action;Journal of the American Heart Association;2017-10-11

3. Liquid chromatography-high resolution-tandem mass spectrometry using Orbitrap technology for comprehensive screening to detect drugs and their metabolites in blood plasma;Analytica Chimica Acta;2017-05

4. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure – TORNADO: a study protocol for a randomized controlled trial;Trials;2017-01-23

5. Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure;Drug Design, Development and Therapy;2015-08